Skip to main content
. 2021 Jun 7;61(3):1026–1034. doi: 10.1093/rheumatology/keab474

Table 4.

Glycaemic, insulin, GLP-1 and lipid parameters at baseline and change with treatment

Variable Baseline (n = 59) Change at month 1 (n = 55) P-value Change at month 3 (n = 53) P-value Change at month 6 (n = 50) P-value
HbA1c (mmol/mol) 38.0 (7.1) −0.9 (−2.2, 0.4) 0.185 0.2 (−1.1, 1.6) 0.748 1.1 (−0.2, 2.5) 0.105
OGTT glucose
 Fasting glucose (mmol/L) 5.3 (4.9–5.8) 0.0 (−0.4, 0.4) 0.912 0.1 (−0.3, 0.5) 0.582 0.5 (0.1, 0.9) 0.012
 30 min glucose (mmol/L) 9.3 (8.2–10.8) −0.1 (−0.7, 0.5) 0.805 0.2 (−0.5, 0.8) 0.577
 1 h glucose (mmol/L) 9.1 (7.0–12.3) 0.0 (−0.7, 0.7) 0.971 0.2 (−0.6, 0.9) 0.632
 90 min glucose (mmol/L) 7.5 (6.5–10.7) −0.1 (−0.8, 0.6) 0.826 −0.3 (−1.0, 0.4) 0.429
 2 h glucose (mmol/L) 6.9 (5.8–8.3) −0.5 (−1.1, 0.2) 0.175 −0.3 (−1.0, 0.4) 0.341
 Glucose AUC (mmol/min/L) 979 (847–1215) −11 (−78, 57) 0.755 8 (−63, 79) 0.829
OGTT insulin
 Fasting insulin (µU/ml) 13.4 (9.1–20.1) 4.7 (1.2, 8.2) 0.008 3.6 (0.1, 7.1) 0.046 5.4 (1.9, 9.0) 0.003
 30 min insulin (µU/ml) 76.0 (49.6–128.7) −0.9 (−23.0, 21.3) 0.940 0.9 (−22.1, 23.9) 0.939
 1 h insulin (µU/ml) 100.2 (59.5–146.9) 10.6 (−11.6, 32.9) 0.349 −4.8 (−28.1, 18.4) 0.683
 90 min insulin (µU/ml) 95.4 (52.1–144.8) 8.8 (−9.4, 27.1) 0.344 −11.7 (−30.5, 7.1) 0.224
 2 h insulin (µU/ml) 65.7 (42.9–116.7) −8.2 (−26.7, 10.3) 0.384 −15.0 (−34.3, 4.4) 0.129
 Insulin AUC (µU/min/mL) 10209 (6549–13 600) 422 (−1411, 2255) 0.652 −554 (−2477, 1369) 0.572
OGTT GLP-1
 Fasting GLP-1 (pmol/L) 5.81 (4.25–7.58) 0.94 (−0.09, 1.97) 0.073 0.94 (−0.10, 1.99) 0.077 0.88 (−0.19, 1.94) 0.106
 30 min GLP-1 (pmol/L) 13.49 (10.22–20.37) −2.87 (−8.93, 3.19) 0.353 −0.26 (−6.59, 6.07) 0.936
 1 h GLP-1 (pmol/L) 10.20 (7.16–17.46) −3.44 (−6.37, −0.51) 0.021 −1.51 (−4.57, 1.55) 0.334
 90 min GLP-1 (pmol/L) 8.21 (5.04–12.60) −0.80 (−3.64, 2.05) 0.584 −0.92 (−3.85, 2.00) 0.536
 2 h GLP-1 (pmol/L) 5.87 (4.40–9.94) −1.53 (−3.49, 0.44) 0.128 −0.56 (−2.61, 1.50) 0.596
 GLP-1 AUC (pmol/min/L) 41.21 (28.82–58.60) −7.75 (−20.62, 5.12) 0.238 −2.75 (−16.19, 10.69) 0.689
HOMA indices
 HOMA-IR 2.0 (1.3–3.0) 0.65 (0.19, 1.11) 0.006 0.50 (0.03, 0.96) 0.037 0.75 (0.27, 1.23) 0.002
 HOMA-%S 50.1 (33.4–77.5) −10.4 (−16.2, −4.6) <0.001 −6.6 (−12.5, −0.7) 0.029 −8.7 (−14.7, −2.6) 0.005
 HOMA-%β 122 (102.3–168) 17.3 (4.6, 30.0) 0.008 14.6 (1.7, 27.5) 0.026 10.0 (−3.2, 23.3) 0.137
Lipid profiles
 Total cholesterol (mmol/L) 4.7 (1.0) −0.2 (−0.4, −0.0) 0.043 −0.2 (−0.4, 0.0) 0.086 0.1 (−0.1, 0.3) 0.451
 HDL-C (mmol/L) 1.3 (1.1–1.6) −0.1 (−0.1, −0.0) 0.040 −0.1 (−0.1, −0.0) 0.030 −0.0 (−0.1, 0.1) 0.912
 LDL-C (mmol/L) 2.7 (0.9) −0.1 (−0.3, 0.0) 0.092 −0.1 (−0.3, 0.0) 0.067 0.0 (−0.2, 0.2) 0.952
 Triglycerides (mmol/L) 1.2 (0.8–1.8) −0.0 (−0.3, 0.2) 0.922 0.1 (−0.2, 0.3) 0.444 0.2 (−0.1, 0.4) 0.178

Baseline values are mean (s.d.) (normally distributed) or median (IQR) (not normally distributed variables); mean change (95% CI) compared with baseline. Values in bold are statistically significant, i.e. P < 0.05. Baseline data available for n = 59. HOMA: homeostasis model assessment; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-%β: beta-cell function; HOMA-%S: insulin sensitivity.